Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Set-up of a biobank for patients with an estimated date of infection seroconverters: store plasma and cells samples at initial contact and during follow-up for future analysis and analysis in international collaborative cohort seroconverters.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| HIV+ patients with an estimated date of seroconversion | It was estimated that 564 individuals, will be enrolled at the Blood Bank Medical Centre, including 364 individuals already followed-up (former PRIMOCI ANRS 1220 cohort started in 1997) and 200 newly enrolled individuals in this study. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Natural history of HIV infection in Sub-Saharan Africa | Plasmatic HIV viral load and CD4 measured every six months and incidence of morbidity events associated with AIDS | 12 months after ART initiation |
| Measure | Description | Time Frame |
|---|---|---|
| Estimate the probability of disease progression after HIV seroconversion | Disease progression will be estimated with CD4 cell loss and time from seroconversion to clinical AIDS, death and antiretroviral therapy initiation | 12 months after ART initiation |
| Evolution of markers of HIV infection and immunity |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
All HIV infected individuals that will have had a contact with the Blood Bank Medical Center since 1992.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Albert Kla Minga, MD, PhD | CMSDS, Abidjan, Côte d'Ivoire | Principal Investigator |
| Patrick Coffie, MD, PhD | Programme PACCI, Abidjan, Côte d'Ivoire | Principal Investigator |
| Charlotte Lewden, MD, PhD | Institut de Santé Publique, d'Epidémiologie et de Développement (ISPED), Bordeaux, France | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Centre Médical du Suivi des Donneurs de Sang (Blood Bank Medical Centre) | Abidjan | Côte d’Ivoire | ||||
Not provided
| Label | URL |
|---|---|
| Sponsor site | View source |
| Methodology centre site | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D015658 | HIV Infections |
| D018450 | Disease Progression |
| ID | Term |
|---|---|
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
| D015229 | Sexually Transmitted Diseases, Viral |
Not provided
Not provided
Not provided
Not provided
Not provided
Plasma and whole blood for PBMC preparation
CD4 count, immune activation, plasma HIV-RNA intracellular, HIV-DNA |
| 12 months after ART initiation |
| Viral genetic diversity description | biomolecular analysis of HIV-1 | Inclusion (J0) |
| Primary resistance to antiretroviral treatment | Frequency of primary resistance to antiretroviral treatment (genotyping) | Inclusion (J0) |
| Metabolic and lipodystrophic disorders | Metabolic analysis (Total Cholesterol, HDL and LDL, Triglycerides) and lipodystrophia measurements | 12 months after ART initiation |
| Incidence of pregnancies | Occurence of pregnancies | 12 months after ART initiation |
| T lymphocytes activation and evolution in seroconverters | Define parameters of activation of T lymphocytes and their evolution since primo-infection among individuals recently infected in West Africa; Expression of markers CD38, HLA-DR, CD28 and CD127 on CD4 and CD8 T cells by flux cytometry | Inclusion |
| T lymphocytes activation and evolution in seroconverters | Define parameters of activation of T lymphocytes and their evolution since primo-infection among individuals recently infected in West Africa; Expression of markers CD38, HLA-DR, CD28 and CD127 on CD4 and CD8 T cells by flux cytometry | 12 months after ART initiation |
| Centre National de Transfusion Sanguine (National Blood Transfusion Centre) |
| Abidjan |
| Côte d’Ivoire |
| D012749 | Sexually Transmitted Diseases |
| D016180 | Lentivirus Infections |
| D012192 | Retroviridae Infections |
| D012327 | RNA Virus Infections |
| D014777 | Virus Diseases |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D007153 | Immunologic Deficiency Syndromes |
| D007154 | Immune System Diseases |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |